Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$120 Mln
P/E Ratio
--
P/B Ratio
0.4
Industry P/E
--
Debt to Equity
0.27
ROE
-0.54 %
ROCE
-42.53 %
Div. Yield
0 %
Book Value
2.75
EPS
-1.61
CFO
$-811.94 Mln
EBITDA
$-1,082.69 Mln
Net Profit
$-1,089.18 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Fate Therapeutics (FATE)
| -32.73 | 17.90 | -11.20 | -79.37 | -69.14 | -47.87 | -14.65 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Fate Therapeutics (FATE)
| -55.59 | -62.93 | -82.76 | -35.65 | 364.64 | 52.53 | 109.14 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and... T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Address: 12278 Scripps Summit Drive, San Diego, CA, United States, 92131 Read more
Founder, CEO, President & Director
Mr. J. Scott Wolchko
Founder, CEO, President & Director
Mr. J. Scott Wolchko
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Fate Therapeutics Inc (FATE) stood at $ 441 Mln as on 31-Dec-24
The share price of Fate Therapeutics Inc (FATE) is $1.11 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Fate Therapeutics Inc (FATE) has given a return of -69.14% in the last 3 years.
Fate Therapeutics Inc (FATE) has a market capitalisation of $ 120 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Fate Therapeutics Inc (FATE) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Fate Therapeutics Inc (FATE) and enter the required number of quantities and click on buy to purchase the shares of Fate Therapeutics Inc (FATE).
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Address: 12278 Scripps Summit Drive, San Diego, CA, United States, 92131
The CEO & director of Mr. J. Scott Wolchko. is Fate Therapeutics Inc (FATE), and CFO & Sr. VP is Mr. J. Scott Wolchko.
There is no promoter pledging in Fate Therapeutics Inc (FATE).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Fate Therapeutics Inc. (FATE) | Ratios |
|---|---|
|
Return on equity(%)
|
-54.21
|
|
Operating margin(%)
|
-1434.52
|
|
Net Margin(%)
|
-1366.46
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Fate Therapeutics Inc (FATE) was $0 Mln.
$0.06
(
